drugset
drugset / Trial / NCT04144582

Sintilimab Combined With Docetaxel for Standard Chemotherapy Failure Non-driver Gene Mutation Metastatic Non-small Cell Lung Cancer

NCT04144582 ↗

Phase 2 Completed 30 enrolled Yongchang Zhang
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the safety and effectiveness of Sintilimab Combined With Docetaxel in Non-driver Gene Mutation NSCLC patients who failed with double platinum-based chemotherapy

Timeline

Start
2019-01-01
Primary completion
2020-09-30
Completion
2021-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Docetaxel Small molecule 75 mg/m2 Intravenous
Subject Sintilimab Monoclonal antibody 200 mg Intravenous

Indications

non-small cell lung carcinoma